HSD3B1 Genotype and Prostate Cancer Outcomes: Nima Sharifi, MD

Men with metastatic castration-sensitive prostate cancer (CSPC) generally experience an initial response to androgen deprivation therapy (ADT), but with time, the cancer invariably becomes castration resistant. A new analysis of data from the phase 3 CHAARTED trial, published last week in JAMA Oncology, shows that men with low-volume metastatic CSPC who have the adrenal-permissive genotype of the HSD3B1 gene experience more rapid progression to castration-resistant disease and shorter overall su...
Continue reading

Metastatic Castration-Sensitive Prostate Cancer: HSD3B1 Genotype Impacts Outcomes

‚ÄčIn metastatic castration-sensitive prostate cancer, both progression to castration-resistant disease and overall survival are negatively impacted by the adrenal-permissive genotype of HSD3B1, according to a new analysis of data from the phase 3 CHAARTED trial.Androgen deprivation therapy (ADT) almost always produces an initial response in metastatic prostate cancer; over time, however, the cancer inevitably develops a resistance to castration. One major way in which this happens is when the tum...
Continue reading

The Current State of CRPC Management With Judd W. Moul, MD, FACS

In the past decade, much progress has been made in the management of castration-resistant prostate cancer (CRPC), with numerous new agents improving outcomes in patients with this disease. However, many challenges still remain. In this interview with i3 Health, Judd W. Moul, MD, FACS, Professor of Urologic Surgery at the Duke School of Medicine, discusses strategies that community oncologists and urologists can utilize to determine the best treatment for their patients. He also discusses the rol...
Continue reading

Urologists Prefer Live CME Activities Over Online

At the 67th Society of Government Service Urologists (SGSU) Kimbrough Urological Seminar, held from January 15th to 19th, 2020, in Charlotte, North Carolina, i3 Health conducted a survey of participants regarding the formats in which they wished to receive continuing medical education (CME). Thirty-six individuals completed the survey, of whom 35 (97.2%) were physicians and other prescribers of medication. Results showed that despite the ever-increasing ubiquity of technology in our society, uro...
Continue reading

Castration-Resistant Prostate Cancer: Guiding Patients Through Treatment With Brenda Martone, MSN, ANP-BC, AOCNP

‚ÄčAndrogen deprivation therapy is a cornerstone of treatment for progressive prostate cancer, but over time, many patients stop responding to this treatment, developing a resistance to castration. Until recently, nonmetastatic castration-resistant prostate cancer (CRPC) lacked effective treatment options; this situation has changed dramatically with the rise of several new agents. Metastatic CRPC is the primary cause of prostate-related mortality, yet advances in treatment are extending survival....
Continue reading

Copyright © 2020 i3 Health. All rights reserved.